Posted by Michael Wonder on 14 Apr 2026
Saphnelo subcutaneous approved in Canada for the treatment of systemic lupus erythematosus
13 April 2026 - Health Canada has granted a notice of compliance for Saphnelo (anifrolumab injection) for subcutaneous self-administration via a single-use auto-injector for adult patients with active, autoantibody positive systemic lupus erythematosus in addition to standard therapy.
The approval by Health Canada was based on positive results from the interim analysis of the Phase 3 TULIP-SC trial.
